{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:51Z","timestamp":1793239431584,"version":"4.5.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-009018"],"award-info":[{"award-number":["INV-009018"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Group B Streptococcus (GBS) can cause invasive disease (iGBS) in young infants, typically presenting as sepsis or meningitis, and is also associated with stillbirth and preterm birth. GBS vaccines are under development, but their potential health impact and cost-effectiveness have not been assessed globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We assessed the health impact and value (using net monetary benefit (NMB), which measures both health and economic effects of vaccination into monetary units) of GBS maternal vaccination in an annual cohort of 140 million pregnant women across 183 countries in 2020. Our analysis uses a decision tree model, incorporating risks of GBS-related health outcomes from an existing Bayesian disease burden model. We extrapolated country-specific GBS-related healthcare costs using data from a previous systematic review and calculated quality-adjusted life years (QALYs) lost due to infant mortality and long-term disability. We assumed 80% vaccine efficacy against iGBS and stillbirth, following the WHO Preferred Product Characteristics, and coverage based on the proportion of pregnant women receiving at least 4 antenatal visits. One dose was assumed to cost $50 in high-income countries, $15 in upper-middle income countries, and $3.50 in low\u2212\/lower-middle-income countries. We estimated NMB using alternative normative assumptions that may be adopted by policymakers.<\/jats:p>\n                    <jats:p>Vaccinating pregnant women could avert 127,000 (95% uncertainty range 63,300 to 248,000) early-onset and 87,300 (38,100 to 209,000) late-onset infant iGBS cases, 31,100 deaths (14,400 to 66,400), 17,900 (6,380 to 49,900) cases of moderate and severe neurodevelopmental impairment, and 23,000 (10,000 to 56,400) stillbirths. A vaccine effective against GBS-associated prematurity might also avert 185,000 (13,500 to 407,000) preterm births. Globally, a 1-dose vaccine programme could cost $1.7 billion but save $385 million in healthcare costs. Estimated global NMB ranged from $1.1 billion ($\u22120.2 to 3.8 billion) under the least favourable normative assumptions to $17 billion ($9.1 to 31 billion) under the most favourable normative assumptions.<\/jats:p>\n                    <jats:p>The main limitation of our analysis was the scarcity of data to inform some of the model parameters such as those governing health-related quality of life and long-term costs from disability, and how these parameters may vary across country contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we found that maternal GBS vaccination could have a large impact on infant morbidity and mortality. Globally, a GBS maternal vaccine at reasonable prices is likely to be a cost-effective intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004068","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T13:22:33Z","timestamp":1678800153000},"page":"e1004068","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-1503","authenticated-orcid":true,"given":"Simon R.","family":"Procter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-6050","authenticated-orcid":true,"given":"Bronner P.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-1040","authenticated-orcid":true,"given":"Proma","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9836-0554","authenticated-orcid":true,"given":"Jaya","family":"Chandna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemis","family":"Koukounari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-5065","authenticated-orcid":true,"given":"Raymond","family":"Hutubessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4573-1443","authenticated-orcid":true,"given":"Joy E.","family":"Lawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"pmed.1004068.ref001","article-title":"Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden","author":"BP Gon\u00e7alves","year":"2022","journal-title":"Lancet Glob Health"},{"key":"pmed.1004068.ref002","doi-asserted-by":"crossref","first-page":"e0258030","DOI":"10.1371\/journal.pone.0258030","article-title":"Burden of invasive group B Streptococcus disease in non-pregnant adults: A systematic review and meta-analysis","volume":"16","author":"A Navarro-Torn\u00e9","year":"2021","journal-title":"PLoS ONE"},{"key":"pmed.1004068.ref003","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children","volume":"65","author":"AC Seale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pmed.1004068.ref004","article-title":"Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina","volume":"101358","author":"P Paul","year":"2022","journal-title":"eClinicalMedicine"},{"key":"pmed.1004068.ref005","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cix654","article-title":"Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review","volume":"65","author":"K Le Doare","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pmed.1004068.ref006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fped.2018.00027","article-title":"Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches","volume":"6","author":"KA Patras","year":"2018","journal-title":"Front Pediatr"},{"key":"pmed.1004068.ref007","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S1473-3099(17)30232-3","article-title":"Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis","volume":"17","author":"PT Heath","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004068.ref008","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S1473-3099(17)30190-1","article-title":"Pertussis and influenza immunisation during pregnancy: a landscape review","volume":"17","author":"B Abu Raya","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004068.ref009","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1016\/j.vaccine.2017.09.087","article-title":"Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics","volume":"37","author":"J Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"pmed.1004068.ref010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2147\/IDR.S203454","article-title":"A Vaccine Against Group B Streptococcus: Recent Advances","volume":"13","author":"C Carreras-Abad","year":"2020","journal-title":"IDR"},{"key":"pmed.1004068.ref011","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S1473-3099(21)00712-X","article-title":"Defeating meningitis by 2030: the WHO roadmap","volume":"21","author":"P. Venkatesan","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pmed.1004068.ref012","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1016\/j.vaccine.2017.08.085","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States","volume":"35","author":"S-Y Kim","year":"2017","journal-title":"Vaccine"},{"key":"pmed.1004068.ref013","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2014.06.003","article-title":"Prevention of group B streptococcal disease in the first 3 months of life: Would routine maternal immunization during pregnancy be cost-effective?","volume":"32","author":"G Oster","year":"2014","journal-title":"Vaccine"},{"key":"pmed.1004068.ref014","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.1993.03510120064032","article-title":"Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis","volume":"270","author":"JC Mohle-Boetani","year":"1993","journal-title":"JAMA"},{"key":"pmed.1004068.ref015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.39325.681806.AD","article-title":"Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses","volume":"335","author":"TE Colbourn","year":"2007","journal-title":"BMJ"},{"key":"pmed.1004068.ref016","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1016\/j.vaccine.2018.09.058","article-title":"Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study","volume":"36","author":"K Giorgakoudi","year":"2018","journal-title":"Vaccine"},{"key":"pmed.1004068.ref017","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.vaccine.2021.04.001","article-title":"Cost-effectiveness of maternal immunization against neonatal invasive Group B Streptococcus in the Netherlands","volume":"39","author":"BA Hahn","year":"2021","journal-title":"Vaccine"},{"key":"pmed.1004068.ref018","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1016\/j.vaccine.2020.02.071","article-title":"Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia","volume":"38","author":"N Ahmed","year":"2020","journal-title":"Vaccine"},{"key":"pmed.1004068.ref019","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.vaccine.2014.01.062","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa","volume":"32","author":"S-Y Kim","year":"2014","journal-title":"Vaccine"},{"key":"pmed.1004068.ref020","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1016\/j.vaccine.2017.07.108","article-title":"Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa","volume":"35","author":"LB Russell","year":"2017","journal-title":"Vaccine"},{"key":"pmed.1004068.ref021","article-title":"The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making","author":"RCW Hutubessy","year":"2021","journal-title":"SSRN J"},{"key":"pmed.1004068.ref022","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","article-title":"Estimating the full public health value of vaccination","volume":"35","author":"BD Gessner","year":"2017","journal-title":"Vaccine"},{"key":"pmed.1004068.ref023","volume-title":"Group B streptococcus vaccine: full value of vaccine assessment","author":"World Health Organization, London School of Hygiene and Tropical Medicine","year":"2021"},{"key":"pmed.1004068.ref024","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019. Available from: https:\/\/population.un.org\/wpp\/Download\/Standard\/Population\/."},{"key":"pmed.1004068.ref025","doi-asserted-by":"crossref","first-page":"e1009001","DOI":"10.1371\/journal.pcbi.1009001","article-title":"Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods","volume":"17","author":"BP Gon\u00e7alves","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"pmed.1004068.ref026","unstructured":"United Nations, Department of Economic and Social Affairs, Statistics Division. SDG Indicators\u2014Regional groupings used in Report and Statistical Annex. [cited 2022 Mar 3]. Available from: https:\/\/unstats.un.org\/sdgs\/indicators\/regional-groups\/."},{"key":"pmed.1004068.ref027","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S2352-4642(21)00022-5","article-title":"Mortality, neurodevelopmental impairments, and economic outcomes after invasive group B streptococcal disease in early infancy in Denmark and the Netherlands: a national matched cohort study","volume":"5","author":"E Horv\u00e1th-Puh\u00f3","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"pmed.1004068.ref028","unstructured":"World Health Organization. Global Health Observatory. [cited 2022 Mar 2]. Available from: https:\/\/www.who.int\/data\/gho\/."},{"key":"pmed.1004068.ref029","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2214-109X(18)30451-0","article-title":"Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis","volume":"7","author":"S Chawanpaiboon","year":"2019","journal-title":"Lancet Glob Health"},{"key":"pmed.1004068.ref030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40273-019-00865-7","article-title":"Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis","volume":"38","author":"S Petrou","year":"2020","journal-title":"PharmacoEconomics"},{"key":"pmed.1004068.ref031","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1016\/j.vaccine.2020.07.050","article-title":"A review of the costs of delivering maternal immunisation during pregnancy","volume":"38","author":"SR Procter","year":"2020","journal-title":"Vaccine"},{"key":"pmed.1004068.ref032","first-page":"43","article-title":"Parents\u2019 utilities for outcomes of occult bacteremia","volume":"154","author":"JE Bennett","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"pmed.1004068.ref033","doi-asserted-by":"crossref","first-page":"e0137095","DOI":"10.1371\/journal.pone.0137095","article-title":"Child Mortality after Discharge from a Health Facility following Suspected Pneumonia, Meningitis or Septicaemia in Rural Gambia: A Cohort Study","volume":"10","author":"AV Chhibber","year":"2015","journal-title":"PLoS ONE"},{"key":"pmed.1004068.ref034","doi-asserted-by":"crossref","first-page":"e9662","DOI":"10.1371\/journal.pone.0009662","article-title":"Long-Term Mortality in Patients Diagnosed with Meningococcal Disease: A Danish Nationwide Cohort Study","volume":"5","author":"C Roed","year":"2010","journal-title":"PLoS ONE"},{"key":"pmed.1004068.ref035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2214.2012.01368.x","article-title":"The association between neurodevelopmental disability and economic outcomes during mid-childhood: Neurodevelopmental disability and economic outcomes","volume":"39","author":"S Petrou","year":"2013","journal-title":"Child Care Health Dev"},{"key":"pmed.1004068.ref036","unstructured":"World Health Organization. WHO Preferred Product Characteristics for Group B Streptococcus Vaccines. Geneva; 2017."},{"key":"pmed.1004068.ref037","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/cid\/cix661","article-title":"Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses","volume":"65","author":"F Bianchi-Jassir","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pmed.1004068.ref038","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1742-4755-10-S1-S2","article-title":"Born Too Soon: The global epidemiology of 15 million preterm births","volume":"10","author":"H Blencowe","year":"2013","journal-title":"Reprod Health"},{"key":"pmed.1004068.ref039","doi-asserted-by":"crossref","first-page":"e0237718","DOI":"10.1371\/journal.pone.0237718","article-title":"Inferring antenatal care visit timing in low- and middle-income countries: Methods to inform potential maternal vaccine coverage","volume":"15","author":"R Baral","year":"2020","journal-title":"PLoS ONE"},{"key":"pmed.1004068.ref040","unstructured":"The World Bank. GDP deflator (base year varies by country) | Data. [cited 2022 Mar 3]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.ZS"},{"key":"pmed.1004068.ref041","unstructured":"The World Bank. Official exchange rate (LCU per US$, period average) | Data. [cited 2022 Mar 3]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF."},{"key":"pmed.1004068.ref042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10198-008-0131-4","article-title":"The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England","volume":"10","author":"E-A Schroeder","year":"2009","journal-title":"Eur J Health Econ"},{"key":"pmed.1004068.ref043","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/INF.0000000000002500","article-title":"Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants","volume":"39","author":"O Salman","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"pmed.1004068.ref044","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1093\/cid\/ciab815","article-title":"Quantifying the Acute Care Costs of Neonatal Bacterial Sepsis and Meningitis in Mozambique and South Africa","volume":"74","author":"C Aerts","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pmed.1004068.ref045","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0000000000001371","article-title":"National Health Care Expenditures Associated With Disability","volume":"58","author":"OA Khavjou","year":"2020","journal-title":"Med Care"},{"key":"pmed.1004068.ref046","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1093\/cid\/ciab782","article-title":"A Financial and Global Demand Analysis to Inform Decisions for Funding and Clinical Development of Group B Streptococcus Vaccines for Pregnant Women","volume":"74","author":"S Malvolti","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pmed.1004068.ref047","doi-asserted-by":"crossref","first-page":"176","DOI":"10.12688\/gatesopenres.13201.1","article-title":"What next after GDP-based cost-effectiveness thresholds?","volume":"4","author":"Y-L Chi","year":"2020","journal-title":"Gates Open Res"},{"key":"pmed.1004068.ref048","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research","volume":"19","author":"B Woods","year":"2016","journal-title":"Value Health"},{"key":"pmed.1004068.ref049","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"key":"pmed.1004068.ref050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bioe.12120","article-title":"Valuing Stillbirths: Valuing Stillbirths","volume":"29","author":"J Phillips","year":"2015","journal-title":"Bioethics"},{"key":"pmed.1004068.ref051","unstructured":"WHO guide for standardization of economic evaluations of immunization programmes. 2nd ed. Geneva: World Health Organization; 2019."},{"key":"pmed.1004068.ref052","volume-title":"Methods for the economic evaluation of health care programmes","author":"M. Drummond","year":"2015","edition":"4"},{"key":"pmed.1004068.ref053","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"D Husereau","year":"2013","journal-title":"BMJ"},{"key":"pmed.1004068.ref054","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","article-title":"National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications","volume":"379","author":"H Blencowe","year":"2012","journal-title":"Lancet"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T13:23:09Z","timestamp":1678800189000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004068","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.11.22277482","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}